CDNA
CareDx, Inc NASDAQ Listed Jul 17, 2014$20.95
Pre-mkt
$21.05
+0.53%
Mkt Cap $1.1B
52w Low $10.96
81.4% of range
52w High $23.24
50d MA $18.66
200d MA $16.86
P/E (TTM)
-53.8x
EV/EBITDA
-1436.6x
P/B
3.8x
Debt/Equity
0.1x
ROE
-2.6%
P/FCF
27.8x
RSI (14)
—
ATR (14)
—
Beta
2.54
50d MA
$18.66
200d MA
$16.86
Avg Volume
704.3K
About
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-c…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | AMC | 0.11 | 0.34 | +209.1% | 21.91 | +2.1% | -5.1% | -5.0% | -1.9% | -4.3% | -5.5% | — |
| Feb 24, 2026 | AMC | 0.02 | 0.12 | +503.0% | 19.25 | -11.3% | -4.1% | -2.2% | -2.5% | -2.6% | -2.3% | — |
| Nov 4, 2025 | AMC | 0.13 | 0.28 | +115.4% | 14.52 | +8.5% | +13.8% | +3.4% | +7.6% | +15.0% | +15.6% | — |
| Aug 6, 2025 | AMC | 0.12 | 0.10 | -16.7% | 13.10 | -7.5% | -7.9% | -8.6% | -10.2% | -4.9% | -7.4% | — |
| Apr 30, 2025 | AMC | 0.06 | 0.09 | +50.0% | 16.88 | -3.4% | -10.7% | -11.1% | -10.1% | -16.0% | -12.5% | — |
| Feb 26, 2025 | AMC | 0.05 | 0.18 | +260.0% | 21.10 | +6.1% | -0.2% | +5.0% | +0.1% | -3.8% | -3.2% | — |
| Nov 4, 2024 | AMC | 0.01 | 0.14 | +1300.0% | 22.93 | -7.1% | -0.1% | +1.2% | +4.1% | +3.1% | +1.8% | — |
| Jul 31, 2024 | AMC | -0.13 | 0.25 | +292.3% | 19.99 | +30.1% | +18.0% | +14.5% | +18.5% | +25.1% | +21.5% | — |
| May 9, 2024 | AMC | -0.19 | -0.03 | +84.2% | 11.06 | +14.2% | +34.1% | +35.4% | +37.8% | +33.6% | +33.6% | — |
| Feb 28, 2024 | AMC | -0.24 | -0.17 | +29.2% | 9.72 | +0.1% | +9.5% | +23.6% | +24.3% | +19.3% | +20.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $21.91 | $22.37 | +2.1% | -5.1% | -5.0% | -1.9% | — | — |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $18.46 | $18.79 | +1.8% | +2.0% | +1.6% | +1.6% | +1.8% | +3.3% |
| Feb 25 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.25 | $17.08 | -11.3% | -4.1% | -2.2% | -2.5% | -2.6% | -2.3% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $20.56 | $20.61 | +0.2% | -3.2% | -5.8% | -5.2% | -6.7% | -5.4% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $16.53 | $16.46 | -0.4% | -9.2% | -5.5% | +1.0% | +1.5% | -1.3% |
| Sep 23 | BTIG | Maintains | Buy → Buy | — | $14.99 | $15.12 | +0.9% | +3.9% | +0.5% | -0.8% | -0.4% | -0.9% |
| Sep 12 | BTIG | Maintains | Buy → Buy | — | $13.53 | $13.40 | -1.0% | +0.0% | +3.6% | +4.8% | +5.7% | +9.2% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.07 | $12.10 | +0.2% | -0.8% | -2.5% | +3.2% | +0.5% | -2.1% |
| Jul 18 | Craig-Hallum | Maintains | Buy → Buy | — | $11.81 | $12.31 | +4.2% | +0.9% | +8.0% | +10.2% | +11.1% | +8.7% |
| May 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.00 | $14.70 | -2.0% | +1.1% | -5.5% | -1.5% | +2.6% | +2.4% |
Insider Trades
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | Sell | 2,688 | $20.68 | $56K | 113,924 | — | — |
Recent Filings
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx (CDNA) experienced an executive change, though specific leadership details weren't disclosed in this brief filing update, potentially signaling internal reorganization that investors should monitor for broader strategic implications.
Apr 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CDNA's partnership with Eurobio Scientific expands its market reach in Europe for diagnostic products, potentially driving revenue growth and reducing geographic concentration risk.
Apr 16
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx appointed Keith Kennedy as principal financial officer, replacing Nathan Smith's resignation as CFO, signaling potential leadership transition and possible strategic shifts in financial management.
Feb 25
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx appointed Keith Kennedy as principal financial officer, replacing Nathan Smith who resigned, signaling potential leadership transition and strategic direction changes for the transplant diagnostics company.
Feb 24
Data updated apr 25, 2026 12:30am
· Source: massive.com